StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
040910.KQ$4750.00-1.18%
Fair $4750.00+0.0%

040910.KQ

ICD Co., Ltd.

Technology / Electronic ComponentsKOSDAQ

$4750.00

-60.00 (-1.18%)

Fairly Valued+0.0%Fair Value $4750.00Fund rank 29/100 · Data gapFallback financials|
SA 29/D
F-Score: 7/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $-7.6B · quality 59.7/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.9%, below the 5% threshold
Thesis & Journal · 040910.KQLocal privado en este navegador · ICD Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$77.6B

P/E

N/A

•

EV/EBITDA

21.1x

↑

ROE

-1.9%

↓

Gross Margin

16.8%

↓

Debt/Equity

0.19

↓
52-Week Range$4750
$3625$6960

TradingView lightweight chart

040910.KQ price, volumen y niveles de valoración

Último $5,010Periodo -86.1%
Fair value: $4,750

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+9.3%

FCF CAGR

—

FCF margin

3.6%

FCF / Net income

-3.75x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $197.04B · net income $-1.90B · FCF $7.13B

2022-FY → 2025-FY

Gross margin

16.8%+6.2% pts

Operating margin

2.3%+5.6% pts

Net margin

-1.0%+2.6% pts

FCF margin

3.6%+19.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$197.04B$197.04B$147.62B$62.27B$150.94B
Net Income$-1.90B$-1.90B$-28.29B$-41.32B$-5.42B
EBITDA$4.16B$4.16B$-12.61B$-37.43B$2.52B
EPS-117.00-117.00-1738.00-2567.00-339.00
Gross Margin16.8%16.8%-2.1%-11.9%10.6%
Operating Margin2.3%2.3%-18.1%-63.1%-3.3%
Net Margin-1.0%-1.0%-19.2%-66.3%-3.6%
Balance Sheet
Debt/Equity0.190.190.350.120.14
Current Ratio1.431.43———
Cash Flow
Free Cash Flow$7.13B$7.13B$-31.13B$-7.64B$-24.18B
Returns
ROE-1.9%-1.9%-29.2%-32.5%-3.5%
Valuation
EV/EBITDA21.1121.11——56.94
P/B0.780.780.771.150.94
Growth & Yield
Revenue Growth33.5%33.5%137.0%-58.7%—
EPS Growth93.3%93.3%32.3%-657.2%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +27.5%

Total return

+27.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-1738.00 → -117.00

Residual

+27.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+27.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.